Experimental hyaline membrane disease in the premature monkey: effects of antenatal dexamethasone.
Experimental hyaline membrane disease in the premature monkey: effects of antenatal dexamethasone.
复制标题
早产猴实验性透明膜疾病：产前地塞米松的影响。
DOI：
10.1164/arrd.1982.126.1.62
复制
发表时间：
1982
期刊：
影响因子：
--
通讯作者：
Hodson,WA
中科院分区：
文献类型：
--
作者：
Kessler,DL;Truog,WE;Murphy,JH;Palmer,S;Standaert,TA;Woodrum,DE;Hodson,WA
采用早产猕猴(Macaca Nemstrina)肺透明膜病(HMD)模型，进行了产前糖皮质激素治疗的随机盲法试验。12只母鼠于妊娠135±1天分别于剖宫产前72、48、24小时给予地塞米松2 mg/剂。12只对照动物接受生理盐水。地塞米松治疗组的婴儿HMD的发生率和严重程度显著低于对照组(50%比92%，p<；0.05)。男性在治疗后的改善明显大于女性。切除的肺的容量-压力行为的不同包括地塞米松治疗的婴儿的扩张性更强(20.6±7.1ml/g干肺比14.7±6.1，p<；0.05)，以及治疗后通气稳定性增强。地塞米松治疗组婴儿肺表面活性物质磷脂的生成增加，表现为肺总磷脂(84.5±8.1 mg/g干肺比75.1±9.9 mg/g干肺，P<0.025.0 5)，肺泡灌洗液磷脂(5.65±3.33 mg/g干肺比3.0 1±1.84 mg/g干肺比3.0 1±1.84 mg/g干肺比1.0 6±1.0 5，P<0.0 5)。地塞米松不影响14C-棕榈酸酯在肺脂中的掺入，但在治疗后标记的更大部分出现在DPC组分中。在该动物模型中，产前地塞米松治疗成功地降低了实验性HMD的发生率和严重程度；治疗的有益效果与胎儿肺功能的加速成熟有关，包括但不限于SAM磷脂的合成代谢。
A blind, randomized trial of antenatal glucocorticoid treatment was conducted using the premature monkey (Macaca nemestrina)model of hyaline membrane disease (HMD). Twelve dams received dexamethasone (2 mg/dose) 72, 48, and 24 h before abdominal delivery at 135 ± 1 days of gestation. Twelve control animals received saline. Infants of dexamethasone-treated dams had significantly lower incidence and severity of HMD than did infants of control animals (50 versus 92%, p < 0.05). Improvement with treatment was markedly greater for males than for females. Differences in volume-pressure behavior of the excised lungs included greater distensibility in the infants from dexamethasone-treated dams (20.6 ± 7.1 ml/g dry lung versus 14.7 ± 6.1, p < 0.05) and enhanced deflation stability with treatment. Accelerated production of surface active material (SAM) phospholipids in infants from dexamethasone-treated dams was indicated by increases in total lung phospholipid (84.5 ± 8.1 mg/g dry lung versus 75.1 ± 9.9, p < 0.025), alveolar lavage fluid phospholipid (5.65 ± 3.33 mg/g dry lung versus 3.01 ± 1.84, p < 0.05), and alveolar lavage fluid disaturated phosphatidylcholine (DPC) (2.47 ± 1.84 mg/g dry lung versus 1.06 ± 1.05, p < 0.05). Incorporation of14C-palmitate into lung lipid was not influenced by dexamethasone, but a significantly greater portion of the label appeared in the DPC fraction with treatment. Antenatal dexamethasone treatment was successful in reducing the incidence and severity of experimental HMD in this animal model; the beneficial effects of treatment were associated with accelerated maturation of fetal pulmonary functions, including, but not limited to, synthetic metabolism Of SAM phospholipid.